百济神州：港股公告：百济神州有限公司截至2024年6月30日止三个月及六个月未经审核业绩以及业务进展最新情况
BeiGene, Ltd.
06160
2024630
13.09
571XIVA
2024630
2024630
2024
202487
20248302024630
1995(Private Securities LitigationReform Act of 1995)
10-Q
202487
Olivier BrandicourtMargaret Han DuganDonald W. GlazerMichael GollerAnthony C. HooperRanjeev KrishanaAlessandro RivaCorazon (Corsee) D. Sanders
2024? 9.2956%GAAPGAAP?
?
6.37107%BCL2sonrotoclaxBTKBGB-16673
? 15
ADC?
BGNE061606882352024
(GAAP)
?(BTKi)
?
BTKi
63063020242023(%)20242023(%)
$ 921,146$ 553,74566%$ 1,668,064$ 964,03673%$ 8,020$ 41,516(81)%$ 12,754$ 79,026(84)%$ 929,166$ 595,26156%$ 1,680,818$ 1,043,06261%GAAP$ (107,161)$ (318,715)(66)%$ (368,509)$ (689,973)(47)%
*
$ 48,464$ (193,051)125%$ (98,877)$ (468,910)(79)%
*GAAP(GAAP)
GAAPGAAP
?? 2024
?
4.79114%60%(CLL)
CLL2024
?
8,100209%
? 2024(EHA)3SEQUOIA
D
?
17pTP53CLL(SLL)(TN)65100%(CR)CR(CRi)48%? (ASCO)EHA
?CLL/SLLBTKi
?
?? 2024
?
1.586%? ASCO3RATIONALE-306
?
(ESCC)? (FDA)
FDAESCC(PDUFA)
20247
SonrotoclaxBCL2? 1,000? R/R(MCL)2
(WM)2(R/R)CLL2sonrotoclax
?
TN CLL3CELESTIAL? 2024EHA
?
R/R CLL/SLLR/R MCL
R/R WMTNR/R
t11; 14R/R1
? FDAR/R WM? R/R CLLR/R MCL320242025
BGB-16673 (BTK CDAC)
? 300R/R MCLR/R CLL
? 2024EHAR/R CLL/SLL
320242025
? BGB-A445OX40LBL-007LAG-3
BGB-15025HPK12024
? BGB-C354(B7H3 ADC)ADC? BGB-R046IL-15
IL-15T(NK)? KRASMTAPRMT5EGFR CDAC
2024
? BGB-43395CDK4
6020241
? BG-68501CDK2BG-C9074(B7H4 ADC)
? LBL-007LAG-3ESCC2024
? (NMPA)
(BLA)? CEA ADCFGFR2b ADCGPC3x4-1BB2024
? BGB-43035(IRAK4 CDAC)
IRAK4
CDAC
?
403.7
?
2024
20246309.292023
5.95
?
114%209%
20246309.212023
5.5466%
?2024630
4.792.24
??
202485%83%
?
20242023
GAAPGAAP20242023
(%)
20242023
(%)$ 454,466$ 422,7647%$ 382,509$ 363,7355%$ 443,729$ 395,03412%$ 363,922$ 331,60710%$ –$ 188(100)%$ –$ –$ 898,195$ 817,98610%$ 746,431$ 695,3427%
20242023
GAAPGAAP20242023
(%)
20242023
(%)$ 915,104$ 831,34810%$ 787,949$ 725,4319%$ 871,156$ 723,53320%$ 736,068$ 614,76120%$ –$ 375(100)%$ –$ –$ 1,786,260$ 1,555,25615%$ 1,524,017$ 1,340,19214%
2024GAAP2024
1,200
(SG&A)2024GAAPSG&A
?
2024SG&A48%71%
2024GAAP66%
4,800GAAP
GAAP2024630GAAP
20246300.09(ADS)1.150.28ADS3.64
20246309,6002.94
2024
202410-Q
10,000 www.beigene.com.cn
1995(Private Securities LitigationReform Act of 1995)
10-Q
+86 10 5895 8058+86 21 3159 1070ir@ beigene.com media@ beigene.com
ADS
ADS
6306302024202320242023
$ 921,146$ 553,745$ 1,668,064$ 964,036 8,02041,51612,75479,026 929,166595,2611,680,8181,043,062 138,13295,990263,067177,779
791,034499,2711,417,751865,283 454,466422,764915,104831,348 443,729395,034871,156723,533 188375 898,195817,9861,786,2601,555,256
(107,161)(318,715)(368,509)(689,973) 13,22515,07029,38531,086 (11,984)(63,818)(10,222)(45,515)
(105,920)(367,463)(349,346)(704,402)
14,48513,67422,20925,166
(120,405)(381,137)(371,555)(729,568)$ (0.09)$ (0.28)$ (0.27)$ (0.54)1,361,082,5671,360,224,3771,358,315,1451,357,211,308ADS$ (1.15)$ (3.64)$ (3.56)$ (6.99)
ADS104,698,659104,632,644104,485,780104,400,870
202420236301231
$ 2,617,931$ 3,185,984
529,449358,027443,260416,122
1,516,4911,324,154
5,712,1795,805,275333,022315,111646,538693,731203,627238,666
1,036,928885,984
2,345,9242,267,948$ 3,366,255$ 3,537,327
(GAAP)GAAPGAAPGAAPGAAPGAAP
GAAPGAAP
GAAP
GAAPGAAP
GAAPGAAP
GAAPGAAPGAAP
GAAPGAAP
GAAPGAAP
6306302024202320242023
GAAPGAAP$ 138,132$ 95,990$ 263,067$ 177,779
2,6842,1805,0294,3601,1778402,3601,639$ 134,271$ 92,970$ 255,678$ 171,780
GAAPGAAP$ 454,466$ 422,764$ 915,104$ 831,348
55,40645,94893,45179,97616,55113,08133,70425,941$ 382,509$ 363,735$ 787,949$ 725,431
GAAPGAAP$ 443,729$ 395,034$ 871,156$ 723,533
75,28857,381125,95798,7414,5196,0469,13110,031$ 363,922$ 331,607$ 736,068$ 614,761
6306302024202320242023
GAAPGAAP$ 898,195$ 817,986$ 1,786,260$ 1,555,256
130,694103,329219,408178,71721,07019,12742,83535,972
188375$ 746,431$ 695,342$ 1,524,017$ 1,340,192
GAAPGAAP$ (107,161)$ (318,715)$ (368,509)$ (689,973)
130,694103,329219,408178,71723,75421,30747,86440,3321,1771,0282,3602,014$ 48,464$ (193,051)$ (98,877)$ (468,910)